After Tivantinib Phase III Flop, ArQule Shifts Focus To Earlier-Stage Assets

ArQule devotes investor call about tivantinib failure in MET-high liver cancer to its other pipeline candidates, including the FGFR inhibitor ARQ 087, which will enter pivotal testing in intrahepatic cholangiocarcinoma, a rare type of liver cancer, this summer.